Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HM-001 (sodium chlorite) intravesical therapy in non-muscle invasive bladder cancer after TURBT
jRCT2051230033Phase 1Active, not recruiting
- Sponsor
- Hoist Therapeutics
- Start
- Sep 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sodium chlorite in non-muscle-invasive bladder cancer (NMIBC), sponsored by Hoist Therapeutics. Primary endpoints: Part 1: Presence or absence of dose limiting toxicity (DLT) and Part 2: Bladder cancer non-recurrence rate up to last observation. Started Sep 2023; status: active, not recruiting.
02
Drugs
sodium chlorite
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on jRCT2051230033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230033.